Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azithromycin controlled-release microspheres - Pfizer

Drug Profile

Azithromycin controlled-release microspheres - Pfizer

Alternative Names: Azithromycin dihydrate microspheres for oral suspension - Pfizer; Azithromycin extended release - Pfizer; Azithromycin SR (2g single dose) - Pfizer; Sustained-release azithromycin - Pfizer; Zmax; Zmax for oral suspension; Zmax SR

Latest Information Update: 12 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antibacterials; Eye disorder therapies; Macrolides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; Pharyngitis; Respiratory tract infections; Tonsillitis
  • Discontinued Otitis media

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 12 Aug 2015 No recent reports on development identified - Phase-III for Community-acquired pneumonia in Japan (PO)
  • 29 Oct 2010 Launched for Acute exacerbations of chronic bronchitis in Canada (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top